Closing Remarks
Criteria for Approvability
Key Conclusions from European Pivotal Efficacy Studies
Excerpts from NIAAA Letter to FDA Division (May 9, 2000)
Interpretation of Acamprosate U.S.A. Multicenter Trial
Acamprosate, 333 mg tablets
The Toll of Alcohol Dependence
Lipha Pharmaceuticals, Inc.